|
1
|
Warner E: Clinical practice, breast-cancer
screening. N Eng J Med. 365:1025–1032. 2011. View Article : Google Scholar
|
|
2
|
Zeichner SB, Terawaki H and Gogineni K: A
review of systemic treatment in metastatic triple-negative breast
cancer. Breast Cancer (Auckl). 10:25–36. 2016.PubMed/NCBI
|
|
3
|
Collignon J, Lousberg L, Schroeder H and
Jerusalem G: Triple-negative breast cancer: Treatment challenges
and solutions. Breast Cancer (Dove Med Press). 8:93–107.
2016.PubMed/NCBI
|
|
4
|
Rosell M, Jones MC and Parker MG: Role of
nuclear receptor corepressor RIP140 in metabolic syndrome. Biochim
Biophys Acta. 1812:919–928. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Docquier A, Harmand PO, Fritsch S,
Chanrion M, Darbon JM and Cavaillès V: The transcriptional
coregulator RIP140 represses E2F1 activity and discriminates breast
cancer subtypes. Clin Cancer Res. 16:2959–2970. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ho PC, Tsui YC, Feng X, Greaves DR and Wei
LN: NF-kB mediated degradation of the co-activator RIP140 regulates
inflammatory response and contributes to endotoxin tolerance. Nat
Immunol. 13:379–386. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herbst EA, Bonen A and Holloway GP:
Changes in nuclear receptor corepressor RIP140 do not influence
mitochondrial content in the cortex. Appl Physiol Nutr Metab.
40:1086–1088. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aziz MH, Chen X, Zhang Q, DeFrain C,
Osland J, Luo Y, Shi X and Yuan R: Suppressing NRIP1 inhibits
growth of breast cancer cells in vitro and in vivo. Oncotarget.
6:39714–39724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu F, Xiao XI, Zhang T, Zou Q, Chen Z, Pei
L, Su J and Yi WJ: Expression of receptor protein tyrosine
phosphatase ζ is a risk factor for triple negative breast cancer
relapse. Biomed Rep. 4:167–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Piroth MD, Petz D, Pinkawa M, Holy R and
Eble MJ: Usefulness of a thermoplastic breast bra for breast cancer
radiotherapy: A prospective analysis. Strahlenther Onkol.
192:609–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moloney N, Sung JM, Kilbreath S and Dylke
E: Prevalence and risk factors associated with pain 21 months
following surgery for breast cancer. Support Care Cancer.
24:4533–4539. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mangolini A, Ferracin M, Zanzi MV,
Saccenti E, Ebnaof SO, Poma VV, Sanz JM, Passaro A, Pedriali M,
Frassoldati A, et al: Diagnostic and prognostic microRNAs in the
serum of breast cancer patients measured by droplet digital PCR.
Biomark Res. 3:122015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De P, Carlson JH, Wu H, Marcus A,
Leyland-Jones B and Dey N: Wnt-beta-catenin pathway signals
metastasis-associated tumor cell phenotypes in triple negative
breast cancers. Oncotarget. 7:43124–43149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang D, Wang Y, Dai Y, Wang J, Suo T, Pan
H and Liu H, Shen S and Liu H: Downregulation of RIP140 in
hepatocellular carcinoma promoted the growth and migration of the
cancer cells. Tumour Biol. 36:2077–2085. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lapierre M, Bonnet S, Bascoul-Mollevi C,
Ait-Arsa I, Jalaguier S, Del Rio M, Plateroti M, Roepman P, Ychou
M, Pannequin J, et al: RIP140 increases APC expression and controls
intestinal homeostasis and tumorigenesis. J Clin Invest.
124:1899–1913. 2014. View
Article : Google Scholar : PubMed/NCBI
|
